Cabaletta Bio, Inc.
CABA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 1.55 | -9.22 | -0.08 |
| FCF Yield | -80.44% | -5.84% | -17.99% | -36.16% |
| EV / EBITDA | 0.29 | -11.19 | -3.76 | 0.54 |
| Quality | ||||
| ROIC | -72.81% | -30.50% | -49.37% | -39.26% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.76 | 0.79 | 0.88 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -66.74% | -11.06% | -38.44% | -28.72% |
| Safety | ||||
| Net Debt / EBITDA | 1.19 | 2.84 | 1.48 | 2.68 |
| Interest Coverage | -167.30 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -373.34 | -1,163.85 | -244.03 | -1,161.73 |